SYRS

Syros Pharmaceuticals, Inc. Common Stock
SYRS

Overview Fund Activity
Delisted

SYRS was delisted on the 19th of March, 2025.

Back to rankings

106 hedge funds and large institutions have $475M invested in Syros Pharmaceuticals, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 44 increasing their positions, 29 reducing their positions, and 12 closing their positions.

Holders
106
Holders Change
+5
Holders Change %
+4.95%
% of All Funds
1.87%
Holding in Top 10
2
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-50%
% of All Funds
0.04%
New
17
Increased
44
Reduced
29
Closed
12
Calls
$1.32M
Puts
$3.17M
Net Calls
-$1.85M
Net Calls Change
-$2.25M

Top Buyers

1
Fidelity Investments
1
Fidelity Investments
Massachusetts
$67.4M
2
RCM
2
RA Capital Management
Massachusetts
$6.73M
3
BlackRock
3
BlackRock
New York
$31.2M
4
Sumitomo Mitsui Trust Group
4
Sumitomo Mitsui Trust Group
Japan
$38.6M
5
Vanguard Group
5
Vanguard Group
Pennsylvania
$20.4M

Top Sellers

1
AIM
1
ARK Investment Management
Florida
$57.7M
2
PCM
2
Portolan Capital Management
Massachusetts
$0
3
CIA
3
Capital Impact Advisors
Massachusetts
$0
4
Millennium Management
4
Millennium Management
New York
$1.26M
5
D.E. Shaw & Co
5
D.E. Shaw & Co
New York
$282K
Name Market Value Shares Shares
Change 		Shares
Change %
Fidelity Investments
1
Fidelity Investments
Massachusetts
$67.4M 9,015,112 +2,374,277 +36%
AIM
2
ARK Investment Management
Florida
$57.7M 7,711,724 -1,329,597 -15%
BCLSI
3
Bain Capital Life Sciences Investors
Massachusetts
$43.3M 5,785,036 – –
Sumitomo Mitsui Trust Group
4
Sumitomo Mitsui Trust Group
Japan
$38.6M 5,166,290 +784,298 +18%
NAMA
5
Nikko Asset Management Americas
New York
$37.7M 5,042,009 +660,017 +15%
BlackRock
6
BlackRock
New York
$31.2M 4,167,964 +842,404 +25%
ABG
7
Ally Bridge Group
New York
$23.5M 3,139,895 +497,395 +19%
FP
8
Flagship Pioneering
Massachusetts
$22M 2,938,494 – –
Vanguard Group
9
Vanguard Group
Pennsylvania
$20.4M 2,732,424 +687,720 +34%
SB
10
Samsara BioCapital
California
$14.8M 2,189,199 – –
O
11
OrbiMed
New York
$13.7M 1,837,500 +275,000 +18%
OFM
12
Omega Fund Management
Massachusetts
$11.7M 1,562,500 – –
AG
13
Artal Group
Luxembourg
$7.67M 1,025,000 +275,000 +37%
EC
14
EcoR1 Capital
California
$7.48M 1,000,000 – –
RCM
15
RA Capital Management
Massachusetts
$6.73M 900,000 +900,000 New
Geode Capital Management
16
Geode Capital Management
Massachusetts
$6.23M 833,008 +242,906 +41%
State Street
17
State Street
Massachusetts
$5.95M 795,345 +68,406 +9%
Citadel Advisors
18
Citadel Advisors
Florida
$5.22M 698,282 +594,005 +570%
BBA
19
Baker Bros. Advisors
New York
$5.16M 690,167 – –
JPMorgan Chase & Co
20
JPMorgan Chase & Co
New York
$4.97M 663,905 -71,967 -10%
Goldman Sachs
21
Goldman Sachs
New York
$4.76M 636,920 +519,038 +440%
Northern Trust
22
Northern Trust
Illinois
$3.89M 519,905 +68,117 +15%
Morgan Stanley
23
Morgan Stanley
New York
$2.8M 374,131 +298,343 +394%
Charles Schwab
24
Charles Schwab
California
$2.72M 363,167 +120,221 +49%
Dimensional Fund Advisors
25
Dimensional Fund Advisors
Texas
$2.63M 351,169 -153,910 -30%
1
2 3 4 5